Huberman LabHow Cannabis Impacts Health & the Potential Risks | Dr. Matthew Hill
CHAPTERS
- 0:00 – 13:00
Introduction, Origins of the Episode, and Scope of Discussion
Huberman introduces Dr. Matthew Hill, outlines his expertise in cannabis biology, and explains that this episode arose from Hill’s public criticisms of a prior Huberman cannabis episode. They agree the conversation will not be a debate but an up-to-date, evidence-based survey on cannabis’ biology, clinical data, benefits, and harms.
- •Dr. Hill studies cannabis effects on stress, feeding, and behavior across development at University of Calgary.
- •The episode was prompted by Hill challenging prior statements about cannabis-induced psychosis and strain differences.
- •Goal is to clarify where science is solid, where it is uncertain, and to update misconceptions.
- 13:00 – 26:10
What Cannabis Is: THC, CBD, Minor Cannabinoids, and Terpenes
Hill defines cannabis as a chemically complex plant containing many cannabinoids and terpenes, but emphasizes that THC is the main driver of intoxicating and psychoactive effects. CBD, while abundant in discourse, is present at low levels in typical street cannabis, has different pharmacology, and is not intoxicating.
- •Cannabis contains 70–100+ cannabinoids; THC (delta‑9‑THC) produces most psychoactive effects.
- •CBD is structurally similar to THC but is non-intoxicating and likely only weakly psychoactive, if at all.
- •Many minor cannabinoids and terpenes (limonene, myrcene, pinene, β‑caryophyllene) are poorly understood biologically.
- •The 'entourage effect' is a hypothesis that non-THC components modulate THC’s effects, but firm data are sparse.
- 26:10 – 35:40
Subjective Effects: What the Cannabis ‘High’ Feels Like and How It’s Studied
The two discuss how people typically describe being high—mild euphoria, altered perception, introspection, changes in time sense and humor—and how labs objectively measure intoxication using rating scales. Hill explains that even placebo cannabis can elicit ‘feeling high’ in experienced users, highlighting strong expectancy components.
- •Reported effects include mild euphoria, altered sensory processing, introspection, time distortion, and sometimes dissociation.
- •Laboratory assessments rely on visual analog scales for ‘high,’ ‘euphoria,’ ‘liking,’ etc.
- •Placebo cannabis can produce reports of being high in experienced users, demonstrating expectancy bias.
- 35:40 – 1:01:00
Endocannabinoid System 101: CB1, CB2, Anandamide, and 2-AG
Hill explains that CB1 receptors are among the most abundant receptors in the brain, mediating THC’s effects, while CB2 are mainly on immune cells. Endocannabinoids anandamide and 2‑AG are produced postsynaptically and act retrogradely to regulate neurotransmitter release and maintain circuit homeostasis.
- •CB1 is widely expressed in brain neurons; CB2 mainly in immune cells, including brain microglia.
- •Endocannabinoids are produced on-demand in the postsynaptic neuron and travel backward (retrograde) to regulate presynaptic release.
- •System maintains homeostasis: prevents runaway excitation/inhibition and tunes plasticity.
- •Dopamine neurons themselves largely lack CB1, but THC affects dopamine indirectly by disinhibiting them.
- •Anandamide: high-affinity, low-efficacy; likely tonic ‘thermostat’ signal.
- •2‑AG: lower affinity, high-efficacy; activity-dependent, drives rapid plasticity and ‘heavy lifting’ adjustments.
- 1:01:00 – 1:18:40
THC vs. Endocannabinoids: Why Getting High Is Not Just ‘Boosting Anandamide’
Hill distinguishes THC’s pharmacology from endogenous cannabinoids. THC is a high-affinity, partial agonist at CB1 that blankets all CB1 receptors regardless of context. By contrast, endocannabinoids are locally and transiently released, making their effects specific. Blocking anandamide breakdown in humans produces measurable stress and fear changes but no intoxication, showing elevating anandamide is not equivalent to THC exposure.
- •THC is a partial CB1 agonist with high affinity but lower efficacy than 2‑AG; it can outcompete 2‑AG but doesn’t ‘super-activate’ receptors.
- •Pharmacologic elevation of anandamide (with FAAH/‘PHA’ inhibitors) in humans reduces stress responses and fear but does not cause a subjective high.
- •THC intoxication largely stems from loss of spatial/temporal precision: all CB1 circuits are hit simultaneously, altering network dynamics.
- •CB2 and peripheral CB1 roles (e.g., inflammation) are distinct from psychoactive effects.
- 1:18:40 – 1:48:00
Feeding and the Munchies: Mechanisms Behind Cannabis-Induced Eating
They dive into how cannabinoids alter feeding circuits and reward, explaining both clinical appetite stimulation and recreational ‘munchies.’ Endocannabinoids and THC act in hypothalamus, nucleus accumbens, and taste pathways to increase motivation for food, override satiety, and enhance hedonic value, especially of sweet, high-calorie foods.
- •CB1 receptors in hypothalamic AgRP and POMC neurons regulate hunger and satiety signaling.
- •Endocannabinoids and THC disinhibit AgRP neurons and interact with leptin, ghrelin, and NPY pathways.
- •Anandamide in nucleus accumbens increases intake of palatable foods.
- •Japanese work shows THC enhances gustatory cortex responses to sweet but not bitter/sour/salty tastes.
- •Hill’s lab: THC causes satiated rats to restart eating and to work extremely hard for sugar, even for devalued or nausea-paired foods.
- •Cannabis likely ‘locks in’ the reward value of food, slowing normal reward devaluation with continued eating.
- 1:48:00 – 2:28:20
THC Pharmacokinetics: Smoking, Vaping, Edibles, and Concentrates
This chapter compares onset, duration, and blood levels of THC under different routes of administration. Hill emphasizes that with flower, users self-titrate regardless of potency but that concentrates and edibles present qualitatively different risk profiles due to higher peaks and/or long-lived metabolites.
- •Smoked/vaped flower: onset 2–5 minutes, peak ~15–30 min, main high mostly gone by 2 hours; blood THC ~100 ng/mL in lab and real-world data.
- •Colorado ‘canna-van’ studies show regular users of 20–30% THC cannabis still average ~100 ng/mL, similar to lab users of 5–9% cannabis—people titrate.
- •High-potency concentrates (dabs, distillates up to 90–98% THC) are much harder to titrate; users often reach 200–300 ng/mL, with more adverse reactions and tolerance.
- •Edibles: delayed onset (45–90 min), low blood THC (2–5 ng/mL) but significant 11‑hydroxy‑THC production via first-pass metabolism; leads to long (4–8 hour) and sometimes overwhelming highs.
- •Most acute ‘overdose’ experiences and pediatric ER visits are from edibles—often due to redosing before onset.
- •THC is highly lipophilic; resides in fat tissues, slowly leaches out; typical heavy users may test positive up to ~30 days, occasionally longer, especially after fat loss or exercise.
- 2:28:20 – 2:48:00
Tolerance, Addiction, and Cannabis Use Disorder
Hill addresses whether cannabis is addictive, distinguishing cannabis use disorder from more lethal addictions like opioids or alcohol. He notes down-regulation of CB1 in heavy users, moderate tolerance, and real functional impairments in a subset of users, while also acknowledging that many daily users function similarly to nightly alcohol users.
- •Cannabis use disorder (CUD) is real; among weekly users, roughly 30% may meet criteria.
- •Classic signs: consuming more than intended, failed attempts to cut down, craving, neglecting obligations, using despite harm, risky use, and withdrawal (irritability, sleep disturbance).
- •PET imaging shows down-regulation of CB1 receptors in chronic users; functional implications still unclear but consistent with tolerance.
- •Tolerance to cannabis is less dramatic than to cocaine, opioids, or alcohol, but more pronounced with high-potency concentrates.
- •Daily or nightly use does not automatically equal CUD; context and consequences matter (e.g., traveling with illegal cannabis vs. one joint before bed).
- 2:48:00 – 3:09:00
Legalization, Use Patterns, and Public Health Observations
Using Canadian data, Hill describes how legalization has changed use patterns across age and sex, with notable increases in older adults and minimal changes in teen use. He also touches on regulatory gaps, budtender misinformation, and pediatric edible poisonings as unintended consequences.
- •Post-legalization in Canada, biggest proportional use increases are among adults 55+, especially women.
- •Teen use (14–18) has remained flat or slightly decreased; baseline was already high (~35–40% lifetime use by grade 12).
- •Emergency visits for children increased after edibles became available, largely due to accidental ingestion of candy-like products.
- •Legalization reduced cannabis-related arrests and associated harms, but ‘legal’ does not mean ‘safe.’
- •Budtenders are primary information source for many consumers, yet generally lack standardized training, leading to spread of myths (e.g., cannabis for morning sickness).
- 3:09:00 – 3:23:00
Hormones, Fertility, and Pregnancy: Mixed and Limited Evidence
They explore claims about cannabis’ effects on testosterone, estrogen, prolactin, sperm, and pregnancy, finding the human literature mixed, often old, and generally showing modest, within-normal-range changes rather than dramatic hormone disruptions. Hill is more concerned about potential sperm quality effects and use during pregnancy, driven mostly by anti-nausea self-treatment.
- •Most studies suggest transient, modest dips in testosterone after THC but within normal ranges; baseline testosterone in users may even be slightly higher in some cohorts.
- •Prolactin generally appears suppressed by cannabinoids, not increased.
- •Evidence that THC can impair sperm quality comes from in vitro and animal work; human data are mixed but warrant caution for couples struggling to conceive.
- •Reported male gynecomastia from cannabis is not well supported in controlled data and could be confounded by puberty, steroids, or underlying conditions.
- •Estimates of cannabis use during pregnancy range from 2–20%; most women who know they are pregnant stop, but some use for morning sickness, which Hill strongly discourages given unknowns.
- •He argues pregnant women should not treat cannabis as a ‘safer’ anti-nauseant than pharmaceuticals with well-characterized teratogenic profiles.
- 3:23:00 – 4:13:00
Psychosis, Schizophrenia, and Bipolar: Fuel on a Fire, Not a Simple Cause
This is the most nuanced section, where Hill unpacks the relationship between cannabis and psychotic disorders. He clearly distinguishes acute drug-induced psychosis from chronic schizophrenia, arguing cannabis can unmask or worsen an underlying vulnerability but that the data do not support claims that it creates schizophrenia out of nowhere in otherwise low-risk people.
- •Acute cannabis-induced psychotic episodes and severe anxiety/panic do occur but are rare relative to overall use.
- •In people with schizophrenia, cannabis reliably worsens positive symptoms (hallucinations, delusions) and prognosis—Hill says cannabis is contraindicated.
- •First-degree family history of schizophrenia or bipolar likely confers enough risk that THC should be avoided.
- •Historical and cross-national data: massive increases in cannabis use since the 1960s have not been accompanied by matching increases in schizophrenia prevalence; Scandinavia shows similar schizophrenia rates despite very low teen cannabis use.
- •Genetic studies show schizophrenia polygenic risk scores predict cannabis use and CUD better than the reverse, suggesting shared vulnerability and self-medication.
- •Hill’s working model: cannabis is ‘fuel on a fire’—it can precipitate earlier onset and more severe courses in those predisposed, but is unlikely to be a sole cause of schizophrenia in someone otherwise at very low risk.
- 4:13:00 – 4:57:00
Driving, Cardiovascular Risks, Lung Effects, and Cyclic Vomiting Syndrome
They briefly touch on cannabis and driving before delving into emerging evidence for cardiovascular risk and a strange syndrome of cannabinoid hyperemesis. Hill underscores that while lethal overdoses like with opioids are virtually nonexistent, there are still significant physical risks that should influence use decisions.
- •Cannabis impairs reaction time, attention, and coordination; roadside THC testing is problematic because heavy users can show higher baseline blood THC than someone acutely high on an edible.
- •THC causes vasodilation and compensatory tachycardia; observational data link cannabis use with increased rates of strokes and cardiac events, especially in those with preexisting cardiovascular disease.
- •Smoking causes chronic bronchitis and emphysema; lung cancer associations are weaker than with tobacco but data are not definitive.
- •Cannabinoid hyperemesis syndrome (cyclic vomiting relieved by hot showers) occurs mostly in very heavy users; mechanisms likely involve thermoregulation/autonomic circuits but remain poorly understood.
- •Hill advises individuals with cardiovascular disease, schizophrenia, bipolar disorder, or strong family histories of these to avoid THC.
- 4:57:00 – 5:42:00
CBD in Detail: Epilepsy, Mechanisms, and Hype vs. Reality
The conversation returns to CBD, where Hill distinguishes solid evidence for high-dose, pharmaceutical CBD in rare epilepsies from weak or absent evidence for over-the-counter CBD products. He details known targets like adenosine transporters and liver CYP enzymes and explains why typical consumer doses are unlikely to reach biologically active levels in the brain.
- •Historically, CBD was largely bred out of street cannabis as growers selected for THC: both share a precursor; more THC means less CBD.
- •In Dravet syndrome and some other pediatric epilepsies, high-dose CBD (e.g., 20 mg/kg/day) significantly reduces seizure frequency.
- •CBD may block adenosine uptake, increasing adenosine (which is sedating, the opposite of caffeine); it also potently inhibits certain liver enzymes, raising blood levels of co-administered drugs (anti-epileptics, warfarin, THC).
- •Allosteric modulation of CB1 by CBD has been shown in vitro but at concentrations far above what people achieve with commercial products.
- •Blinded human studies often find CBD enhances, not reduces, some subjective THC effects, likely by inhibiting THC metabolism.
- •Hill concludes most people taking 5–25 mg CBD gummies or beverages are experiencing placebo effects, not pharmacological ones.
- 5:42:00 – 6:06:00
Strains, Terpenes, and the Indica vs. Sativa Expectancy Problem
Hill dismantles the popular belief that indica and sativa labels predict consistent, distinct highs. He attributes most of the reported differences to marketing-driven expectancy effects, though he acknowledges early but limited evidence that specific terpenes in specific ratios can modulate THC’s anxiogenic or analgesic properties.
- •‘Indica’ vs. ‘sativa’ are botanical terms (plant shape, growth patterns), not chemical categories.
- •Large chemical-analytic datasets show no stable separation: there is more intra-label than inter-label variation.
- •Users’ reports of ‘indica = couchlock’ and ‘sativa = energetic’ line up almost perfectly with package claims, a classic expectancy/placebo signature.
- •Recent blinded studies show limonene can reduce high-dose THC-induced anxiety at very high (likely supraphysiologic) doses; β‑caryophyllene and others are under study for pain modulation.
- •The entourage effect remains a hypothesis: plausible but far from comprehensively mapped.
- 6:06:00 – 6:50:00
Stress, Anxiety, PTSD, and Endocannabinoid-Based Treatments
Drawing on his own research, Hill discusses endocannabinoid roles in stress and anxiety, human trials elevating anandamide, and small but promising work on THC analogs for PTSD nightmares. He differentiates between treating core anxiety disorders and using cannabis as a nightly anti-nightmare tool, and is cautiously optimistic about future endocannabinoid-targeted drugs.
- •Stress rapidly decreases anandamide in the amygdala, facilitating synaptic strengthening and anxiety-like behavior in animal models.
- •FAAH (anandamide breakdown) inhibitors in humans reduce autonomic stress responses and subjective stress and may aid fear extinction, without intoxication.
- •J&J’s FAAH inhibitor showed moderate effects in social anxiety disorder when blood anandamide was substantially elevated.
- •Canadian military trials: nabilone (a THC analog) markedly reduced PTSD-related nightmares in open-label and small double-blind crossover studies, likely via REM/dream modulation.
- •Veterans often report using THC before bed to remove nightmares; this may improve sleep quality and daily function even if it doesn’t ‘cure’ PTSD.
- •Hill’s group and collaborators are actively pursuing endocannabinoid-based approaches for PTSD and anxiety but stress the need for more and larger clinical trials.
- 6:50:00
Closing: Scientific Disagreement, Correction, and Collaboration
They reflect on how their prior public disagreement led to this constructive, detailed discussion, modeling how scientific disputes should be handled: through data, nuance, and willingness to revise. Hill reiterates that he is neither pro- nor anti-cannabis but pro-evidence, and Huberman emphasizes his commitment to updating content as science advances.
- •Hill thanks Huberman for inviting him to correct the record and clarify complex issues rather than arguing via social media.
- •Both note that disagreement and debate are central to scientific progress; this long-form format allows nuance not possible in short clips.
- •Huberman reiterates he does not present himself as infallible and is committed to correcting and refining information when better data emerge.
- •They agree future work on cannabis, psychosis, and endocannabinoids will likely refine many of today’s tentative conclusions.
